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for sensitivity analyses showed cost-savings ranging from € 22,525 to € 996,384 of 
prophylaxis with aPCC vs. on-demand with rFVIIa. ConClusions: Three times/
week aPCC prophylaxis could reduce 16% the total treatment cost of severe HA 
with inhibitor, saving up to € 98,000/patient/year.
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objeCtives: While previous studies have shown that overweight and obesity are 
associated with higher costs, less is known about health care costs by place of 
service (POS) at various levels of BMI. This study measures the impact of BMI as a 
continuous variable on health care cost at different places of service. POS categories 
include: pharmacy, doctor’s office, inpatient hospital, outpatient hospital or clinic, 
emergency department, laboratory, and other. Methods: Using 2003-2012 retro-
spective data from large employers throughout the United States, employees’ BMI 
values were calculated using health risk appraisal data. All study employees were 
> = 18, had > = 12 months of health plan coverage after their index BMI screening 
date, and had no medical claims indicating pregnancy. Employees with BMI< 18 (1st 
percentile) or BMI> 47 (99thpercentile) were excluded. Generalized additive models 
on 12-month post-index POS costs produced estimates of the nonlinear relation-
ship between BMI and cost after controlling for age, gender, marital status, race, 
salary, zip-code region and index year. Results: This study included 71,633 eligible 
employees; 32.0% were female. The average BMI, age and annual salary were 27.3, 
39.8 years and $81,382, respectively. Costs increased significantly with BMI in each 
POS (P< 0.001). Total adjusted annual per-employee health care cost estimates at BMI 
values of 25, 30, 35, and 45 were $3043, $3932, $4357, and $7248, respectively. Cost 
estimates by POS at these BMI values were: Pharmacy ($706, $903, $1106, $1372), 
Inpatient ($398, $678, $643, $2440), Outpatient ($799, $1057, $1113, $1516), Office 
($939, $1044, $1174, $1495), Emergency ($131, $159, $200, $186), Laboratory ($34, $38, 
$46, $43), and Other ($35, $53, $74, $196), respectively. ConClusions: Employees 
with higher BMI levels incurred more cost at each of the 7 places of service. Because 
of the high prevalence of overweight and obesity, these costs represent a significant 
burden for US employers.
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objeCtives: This study determines the distribution of health care costs by place 
of service (POS; pharmacy, doctor’s office, inpatient hospital, outpatient hospital 
or clinic, emergency department, laboratory, and other) among employees based 
upon body mass index (BMI). Methods: Using 2003-2012 retrospective data from 
large employers throughout the US, employees’ BMIs from health risk appraisal data 
defined three main cohorts (BMI< 27 [normal weight], 27< = BMI< 30 [overweight] and 
BMI> = 30 [obese]). The 27< = BMI< 30 cohort was further divided into 3 comorbidity 
subcohorts: those without diabetes, hypertension or dyslipidemia (NonT2DHtnDys), 
those with hypertension or dyslipidemia without diabetes (HtnDys), and those with 
diabetes with or without hypertension or dyslipidemia (T2D). All eligible employees 
were aged> = 18, had > = 12 months post-index health plan coverage, and had no 
pregnancy claims. Annual post-index costs were compared between cohorts and 
between subcohorts using two-part regression modeling, controlling for age, gender, 
marital status, race, salary, region, and index year. Results: This study included 
39,696 (BMI< 27), 14,281 (27< = BMI< 30), and 18,801 (BMI> = 30) eligible employees, 
with total adjusted health care costs of $3,191, $3,695, and $4,844, respectively. 
Employees with higher BMI were significantly more likely to incur health care costs 
in every POS category. Obese employees (BMI> = 30) had particularly high inpatient 
costs compared to other cohorts, averaging twice the cost of the BMI< 27 cohort 
($919 vs. $431, P< 0.05). Total costs among subcohorts of 27< = BMI< 30 were $2,863 
(NonT2DHtnDys), $5,271 (HtnDys), and $7,594 (T2D). NonT2DHynDys employees had 
significantly lower health care cost than other subcohorts in every POS category. 
The T2D subcohort had significantly higher pharmacy, inpatient, doctor’s office, 
laboratory and other health care costs when compared to HtnDys. ConClusions: 
Employees with higher BMI incurred higher average health care costs than other 
employees at all places of service. Comorbidities, particularly diabetes, exacerbate 
health care costs of overweight employees. This represents a significant economic 
burden for US employers given the high prevalence of overweight and obesity.
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objeCtives: Hemophilia A is rare bleeding disorder where patients have defective 
or deficient levels of coagulation factor VIII (FVIII). Recombinant FVIIII (rFVIII) are 
manufactured to treat the patients, either as a full-length rFVIII (FL-rFVIII) mol-
ecule replicating natural human FVIII or with the B-domain deleted (BDD-rFVIII). It 
has been suggested that Deletion of B domain had been implemented to improve 
production profitability. However, this deletion has been shown to induce increase 
factor consumption by 32.8% in the US (Epstein 2011) and also may increase the 
risk of developing inhibitors for previously treated patients (PTP) Hazard Ratio= 10.8 
(Aledort 2011). Both differences can have an important impact on patient health 
and on the national health care budget. Methods: A Excel-based decision tree 
model had been developed to compare the overall cost to treat severe haemophilia 
A patients from a health care system perspective with the most used FL-rFVIII and 
objeCtives: To assess the cost-effectiveness of ferric carboxymaltose (FCM) and 
iron sucrose (IS) in the correction of iron-deficiency anaemia (IDA) before elec-
tive major surgery in non-cardiac surgical patients and predict potential budget 
expenses for the day care services and blood transfusions. Methods: The pharma-
coeconomic model was developed based on the data from multicentre prospective 
study (E. Bisbe et al., 2011) on the efficacy of FCM and IS for correcting preopera-
tive anaemia in patients undergoing major elective non-cardiac surgery. The cost-
effectiveness of two intravenous iron formulations was measured as total costs of 
medicines and day care services per one patient attained iron replenishment or per 
one patient without IDA at the end of treatment. Budget impact analysis included 
expenses for the day care services and blood transfusion procedures during intraop-
erative and/or postoperative period. Sensitivity analysis was performed by including 
in the model of iron sucrose similars (ISSs). It was considered that treatment with 
ISSs requires dose increase up to 120-135% of dose of the original IS (E. Lee et al., 
2013; J. Rottermbourg et al., 2010). Results: The clinical efficacy of FCM was higher 
compared to that of IS, this was also reflected in better pharmacoeconomic profile 
of FCM. The CERs were 14,473.61 RUB and 15,222.83 RUB per one patient attained 
iron replenishment in the FCM and IS groups, respectively. Treatment with FCM was 
associated with 2.5-fold lower costs of day care services and 2.7-fold lower expenses 
for blood transfusion procedures. Additional expenses for the day care services were 
required for patients received ISSs due to increased frequency of injections; this was 
resulted in the highest CERs in the ISS group. ConClusions: The present study 
has demonstrated that administration of FCM is economically effective strategy to 
replenish body iron stores and correct IDA in surgical patients.
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objeCtives: Although there are several hemostats available, drawbacks include 
limitations with efficacy on first attempt and sub-optimal ease-of-use. Literature 
suggests that more efficacious hemostats may avert hospital resources and offset 
upfront acquisition costs. A study was conducted to estimate the cost impact of a 
novel fibrin sealant patch (i.e., EVARREST™) versus standard of care (SoC) in mild-
moderate and problematic soft tissue surgical bleeding. Methods: An economic 
model was developed to quantify 30-day cost impact of EVARREST from a U.S. hospi-
tal perspective. Key resources, collected from two trials, included quantity of initial 
treatment and re-treatment, operating time, hospitalization, transfusion risk, amount 
transfused, and ventilator utilization. SoC was composed of Surgicel (mild-moderate 
bleeding) or Surgicel (88%) and conventional methods (12%) (problematic bleeding). 
The primary analysis included resources clinically related to the significant hemo-
stasis benefit of EVARREST vs. control (i.e., initial and re-treatment, operating time 
and transfusion). A secondary analysis included all resources collected. Published 
data on U.S. costs were applied to resource use. Results: In problematic bleeding, 
the primary analysis predicted that EVARREST is cost-savings for the hospital vs. 
SoC (-$462 USD per patient) with robust one-way sensitivity results (range: -$199 
to -$6,212 USD). In mild-moderate bleeding, EVARREST acquisition cost is partially 
offset with a cost impact of $507 USD per patient (sensitivity range: $175 to $851 USD). 
Secondary analyses predicted further resource reduction with EVARREST leading 
to cost-savings (-$5,096 USD per patient) or reduction in cost impact ($233 USD per 
patient) for problematic and mild-moderate bleeding respectively. ConClusions: 
This analysis suggests that the hospital cost impact of EVARREST depends on type 
of bleed. In problematic soft tissue bleeding, EVARREST may result in important cost 
savings for hospitals, in addition to meeting an important unmet need. Further study 
in additional populations may be required to confirm findings.
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objeCtives: To estimate the treatment cost of prophylaxis and acute break-
through bleeds with Activated Prothrombin Complex Concentrate (aPCC) versus 
on-demand therapy with recombinant Factor VIIa (rFVIIa) for severe hemophilia 
A (HA) with inhibitor patients, from the Spanish Healthcare System perspec-
tive. Methods: A cost-analysis model was used to compare annual cost per 
patient of aPCC prophylaxis versus rFVIIa on-demand treatment. Cost estimation 
included prophylaxis pharmaceutical costs (aPCC), on-demand pharmaceutical 
treatment for bleedings, bleeding events management (excluding factor), surgeries 
and HA management. Prophylaxis regimen was 75.72IU/kg three times per week. 
Total dosage for each hemorrhagic event was 673.46µg/kg for rFVIIa and 233.13U/
kg for aPCC, annual number of bleedings was 25 for on-demand therapy and 8 
for prophylaxis, assuming 69% reduction due to prophylaxis. A baseline bleed-
ing management cost (€ 2,971) was estimated based on resource use provided 
by an expert panel for four bleeding sites (joints [62.5%], muscle and soft tissue 
[28.6%], mucous membranes [3.6%] and other sites [5.4%]). Drug (ex-factory price 
with mandatory 7.5% rebate) and unitary costs (€ , 2013) were obtained from local 
databases. Results: Estimated annual treatment cost of prophylaxis with aPCC 
(€ 523,473) was lower than on-demand treatment with rFVIIa (€ 622,183). Based 
on the total agent consumption (789,109IU [aPCC] and 1,050,067µg [rFVIIa]) the 
pharmaceutical cost accounted for € 496,350 for aPCC (14.6% on-demand bleed-
ings and 85.4% prophylaxis) compared to € 543,866 for rFVIIa (average bleeding 
cost of € 9,062 [aPCC] and € 21,556 [rFVIIa]). Yearly bleedings cost was € 23,770 for 
aPCC versus € 74,963 for rFVIIa. A baseline cost for HA management (€ 2,645) and 
an average cost of surgeries (€ 708/year) were estimated for both strategies. Results 
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on the prevalence of the disease has led to a cost study using a “top-down” method. 
Sensitivity analyses were conducted on the following cost parameters: medical and 
drugs costs in primary care, costs of public and private hospitalizations - chosen 
according to their weight in the pathway described by the Delphi Panel. Results: 
The social security paid a total of € 5,612,842 for 1377 AI patients in 2011. The annual 
cost per patient is therefore € 4,076, including 62% for primary care expenses, 29% 
for public hospital expenses and 9% for private hospital. The total population with 
AI is estimated between 26,000 and 30,000 patients, leading to a total cost ranging 
from € 106M and € 122M. A 1% reduction in hospital spending would generate a gain 
of € 430,000 to € 500,000 per year. ConClusions: Despite AI concerns few patients, 
significant costs are borne by Social Security. An increased compliance and a better 
management of symptoms such as fatigue could help optimizing this cost.
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objeCtives: Painful diabetic neuropathy (PDN) is a complication of diabetes mellitus. 
The aim of this research was to describe the epidemiology and economic burden result-
ing from PDN in Europe. Methods: A systematic literature review was performed 
according to a pre-defined search strategy and review criteria in Embase and PubMed 
from 2003 to 2012. Conference proceedings and Health Technology Assessment (HTA) 
organizations’ websites were also searched from 2010 to 2012. Results: In total, 23 
original studies were identified that covered either epidemiology (n= 16) or economic 
burden (n= 7) for PDN patients in Europe. 13 - 26% of European diabetes patients are 
reported to develop PDN. Health care costs per PDN patient were between € 2,441 and 
€ 2,963 per annum in UK and Spanish studies, respectively. Inpatient care, medical visits 
and drug costs accounted for the majority of the total costs, although drug costs can 
vary widely depending on the choice of medication. Health care costs for PDN lead 
to a high total economic burden for European countries. Considering the identified 
prevalence data and cost estimates, the estimated total annual health care burden 
for the UK would be approximately € 1.7 billion, from a payer perspective. In addition, 
PDN is significantly associated with disruptions in employment status and productiv-
ity loss, primarily driven by impairment while working (presenteeism), resulting in 
average European per-patient productivity losses of € 10,484 per annum. Pain severity 
highly influences economic outcomes: higher severity has been linked to significant 
increases in resource use, productivity losses and health care costs. ConClusions: 
The large number of PDN patients combined with the cost per patient results in a high 
economic burden of PDN for European countries. More severe pain results in increased 
resource use and costs for payers and society; therefore, more effective PDN treatments 
will lead to patient as well as economic benefits.
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objeCtives: Obesity and its comorbidities are among the primary challenges that 
health systems face globally. Obesity is rapidly becoming a problem in Turkey as well. 
Recent research has revealed that 30.3% of the population is obese(20.5% of males, 
41% of females) of which 2.9% of the obese population is classified under the morbid 
obese category. The 2003 Burden of Disease Study also concluded that 26.006 deaths for 
males and 31.136 deaths for females could be averted by decreasing the ratio of obese 
population. Methods: The objective of this study is to find out the economic impact 
of obesity with its possible economic benefits of obesity surgery for Turkey. Results: 
Literature search and expert panel are the main methodologies used in the study. A 
comprehensive literature search was undertaken with key words in PubMEd to find 
out the extent of obesity and its comorbidities and treatment methods in Turkey. Cost 
of obesity for Turkey was calculated depending on the published literature. An expert 
panel questionnaire form was designed after the literature search aiming at finding the 
cost. The form was sent to the experts in advance and a panel discussion was under-
taken to reach a consensus. After the consensus building phase the economic ben-
efits of obesity surgery were estimated based on the price tariff declared by the Social 
Security Institution(SGK). ConClusions: Cost of obesity for Turkey was estimated as 
US$ 787.184.000 for 2012. It was the 1.05% of gross domestic product of Turkey. SGK 
pays US$ 1707 weighted average for obesity surgery. It was estimated that return of 
investment on obesity surgery can be possible after the third year of surgery. The study 
indicated that obesity has a great impact to Turkish economy. On the other hand, obesity 
surgery can have a positive impact with its economic benefits to Turkish health system.
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a SYSteMatiC liteRatuRe Review on the ePideMiologY and eConoMiC 
BuRden of anaeMia aSSoCiated with ChRoniC kidneY diSeaSe
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objeCtives: The epidemiological and economic burden associated with anaemia 
in patients with chronic kidney disease (CKD) in Europe has not been explored 
recently using systematic literature review (SLR) methods. Therefore, an SLR was 
conducted to assess these topics. Methods: A systematic search was conducted 
of MEDLINE- and EMBASE-indexed literature on anaemia in CKD from 2007 to 2012 
for publications on epidemiology and economic burden. Data from included articles 
were abstracted into a pre-designed template and synthesised using qualitative 
methods. Results: The review identified 19 studies reporting on epidemiology and 
nine on economic burden. The prevalence of anaemia among patients with CKD var-
ied widely by setting, being generally lower in those from the general population and 
BDD-rFVIII in Europe. Clinical data are from the published literature. Pharmacy cost 
of rFVIII, immune tolerance induction (ITI) and bypassing agents for patients who 
developed inhibitors are considered from French health care perspective. Results: 
Both products are listed and reimbursed at similar unit price whereas the overall 
cost to treat a patient with BDD-rFVIII is higher considering the increased con-
sumption on prophylaxis and the risk of developing an inhibitor for PTPs. This may 
be translated into an increase cost of 36% over 1 year and 40% over 3 years when 
treating children and adult PTPs with prophylaxis. ConClusions: The cost study 
confirms the cost advantage of rFVIII (FL-rFVIII) as well as the need to compare the 
rFVIII based on the overall cost and not on the price per unit.
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objeCtives: To quantify the total societal costs of Neuropathic Pain (NP) in Spain 
following a bottom-up prevalence approach. Methods: The sample was drawn 
from the 2012 Adelphi NP Disease Specific Programme, a cross-sectional survey of 
413 primary care physicians and specialists and their consulting patients across the 
EU5. Physicians completed patient record forms for 826 patients in Spain including 
patients’ socio-demographic information, treatment history and resource utiliza-
tion. Additionally, 577 patients voluntarily completed another questionnaire that 
included the Work Activity and Productivity Impairment Questionnaire (WPAI). 
Health-related costs were collected and adjusted to 2012 prices when needed. 
For professional caregivers’ costs and work losses, Spanish average salaries were 
used. Results: The 826 patients included accounted for a total of € 2,676,893.83, 
an average of € 3,240.79 per patient, with 72% (€ 2,350) of these being health related 
costs, including drugs (50%), consultations (11%), surgical (9%) and non-surgical (2%) 
procedures. Working losses related with patients’ sick leave (as reported by doctors) 
accounted for 17% (€ 555) of the costs and professional caregiving added up to 10% 
of the total costs. The results were extrapolated to national prevalence figures of 
2012 excluding patients assumed to be non-treated. The societal costs for 2012 were: 
health-related costs € 514,583,543, work losses € 119,417,964 and professional caregiv-
ers € 72,204,921. Additionally, 91% of the caregivers were non-professional. 191 (33%) 
of the 577 patients completed the WPAI with an Overall Work Impairment score of 
55%. Finally, 183 (33%) of the patients stated that NP prevented them from working 
at some point, with 26 patients stating this was “permanently”. ConClusions: 
The economic impact associated with Neuropathic Pain (NP) implies substantial 
annual costs to the Spanish National Health Service of more than € 500 Mio. and a 
large burden on patients’ lives and their families. The results shown here suggest 
that an important part of the real cost is still hidden.
PSY21
exPloRing the BuRden of illneSS of heReditaRY angioedeMa in the 
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objeCtives: Hereditary angioedema (HAE) is a rare but potentially life-threaten-
ing condition with intermittent and unpredictable oedema affecting the larynx, 
abdomen and extremities. This study aims to define the burden of HAE in England 
and Scotland as published data are limited. Methods: A comprehensive, cross-
sectional, retrospective study of the burden of HAE (type I and II) in England and 
Scotland. Three data collection methods: 1) secondary care data identified using 
Hospital Episode Statistics based on D.84.1 diagnostic code (defects in complement 
system, C1-esterase inhibitor deficiency); 2) primary care data accessed through 
The Health Improvement Network (THIN) database using C-376-000 HAE diagnostic 
code. Both database analyses identified patients diagnosed ≤ 10 years and include all 
episodes ≤ 2years. Costs were calculated using most up-to-date best-matched HRG 
tariffs. 3) Primary research in five secondary care centres in England and Scotland 
collecting information on > 100 patients (> 18 years) via medical records ≤ 2years, 
matched with patient self-completion questionnaires and centre interviews. 
Selected centres represent different approaches to HAE management to ensure a 
national representative sample. Results: Data collection from all three phases of 
the study is on-going. Early results from 1) indicate 1,174 HAE patients admitted 
to hospitals in England, for any reason, in the past two years. Mean length of stay, 
including day cases, was 2.8 days. The annual total cost of secondary care in England 
was £3,227,149, corresponding to per HAE patient cost of £2,749. ConClusions: 
This is the first comprehensive UK HAE cost of illness study, providing a compre-
hensive understanding from both NHS and patient perspectives. Important insight 
into patient demographics, pathway of care, treatment patterns, and any regional 
or sub-population differences in the standard of care will be provided, helping to 
raise disease awareness in the UK.
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objeCtives: Adrenal insufficiency (AI) is a rare disease caused by a deficiency in hor-
mone synthesis by adrenal glands, due to either the destruction of the glands (primary 
AI: PAI) or hypothalamic / pituitary causes (secondary AI: SAI). Patients are treated 
with hormone replacement therapy, mainly hydrocortisone. Our aim was to assess the 
cost of AI management in France Methods: We used data from the French National 
Health Insurance (Social security) on patients who benefited from a long duration 
disease status N°31 for their AI in 2011 (primary and secondary combined) on the one 
hand, and the results of a Delphi Panel survey on the other hand. This survey, involv-
ing 15 endocrinologists from academic hospitals, was designed to better understand 
the patients’ pathway in the absence of guidelines. An epidemiological approach 
